Substance in Milk helps prevent HIV replication

It is interesting to read that a property in milk helps in combating infections among HIVs. Lactoferrin, a substance found in milk, was seen to combine to surfaces of Immune (CD4+) cells and block HIVs from attaching to them and cause damage to them.

Although I have not made a complete research on the net about this one, I was able to read some notes where Lactoferrin was noted to have some effect on how HIV infection progresses in the body of infected individuals. This is somehow difficult for lactoferrin should be made available in the blood unaltered for it disintegrates when it passes through the digestive system rendering it innefective when absorbed.

But just to give you some idea on the contents of the original article, please read Property Found In Dairy Products Could Thwart HIV. Start drinking your daily dose of milk today. :)

GenePro HIV/AIDS Vaccine: Innovation by ImmunoGenetix

GenePro HIV/AIDS Vaccine: Innovation by ImmunoGenetix

We can now see that pharmaceuticals and various scientific laboratories left and right are developing effective ways to combat HIV/AIDS through the development of vaccines and other medicinal remedies for those who are already infected.

ImmunoGenetix, a biotechnology company in Lenexa, KS, is currently working on developing immunotherapies that specifically helps people who contracted HIV and those suffering from its long-term effect – AIDS.

The vaccine GenePro is currently completing its phase I clinical trial to establish vaccine effectiveness and safety and observe antibody activity among patients infected by HIV/AIDS.

Vaccines are specifically interesting for it limits the amount of antiviral drug cocktails that usually requires 15 to 20 tablets a day. Aside from the obnoxious side effects, the current antiviral medicines are expensive which in turn fails to reach all consumers of various economic statuses.

Recent attempts to create an effective vaccine are hampered by the virus’ ability to mutate. This apparent change makes it even difficult to create one type of vaccine that will protect an individual from the many strains and types of HIV.

For more information on ImmunoGenetix Therapeutics, please visit their site at ImmunoGenetix.com.

HIV vaccine MVA-BN starts Clinical Phase I/II Trial

It’s interesting to know that a lot of efforts are being put on the development of effective vaccine that will finally eradicate HIV/AIDS in the world. Despite of all this, it shows that we are way too far from reaching the point of success. Victory may be distant but shortcut is just around the corner!

Bavarian Nordic AS, one of the leading Europe-based pharmaceutical companies, is on its Clinical Phase I/II of its HIV vaccine. It is also developing effective vaccine against smallpox and other cancer including breast and prostate cancer.

The pharmaceutical company will provide feedback about the outcome of the research study by the second half of next year. The vaccine MVA-BN polytope is expected to provide protection against common or all types of HIV strains which exhibits common surface structure (protein coat).

For information regarding drugs and other vaccines developed by Bavarian Nordic AS, please visit the site.